Residency · Residency · Psychiatry

Electroconvulsive Therapy: Indications and Technique

Overview and History

Evolution of ECT

Introduced in 1938 by Cerletti and Bini; initially performed without anesthesia or muscle relaxation. Modern ECT uses brief-pulse or ultra-brief-pulse stimulation under general anesthesia with muscle relaxation -- dramatically safer and better tolerated. Remains the most effective treatment for severe depression and the most rapid-acting treatment for several psychiatric emergencies. Despite strong evidence, ECT remains underutilized due to stigma, media misrepresentation, and access barriers.

Indications

Primary Indications

Treatment-resistant depression (TRD): failure of 2+ adequate antidepressant trials; ECT response rates 50-70% even in TRD. Severe depression with psychotic features: ECT is first-line; remission rates ~80-90% (superior to pharmacotherapy alone) Acute suicidality: ECT provides the most rapid reduction in suicidal ideation (faster than any pharmacotherapy including ketamine in head-to-head comparisons) Catatonia: ECT is definitive treatment, especially when benzodiazepines fail or in malignant catatonia. Bipolar depression and mania: effective for both poles, especially treatment-resistant cases. Pregnancy: considered one of the safest treatments in pregnancy when severe depression or psychosis requires urgent intervention (avoids fetal drug exposure)

Secondary/Relative Indications

Severe depression in the elderly (high efficacy, avoids polypharmacy) Parkinson disease with depression (motor benefit in addition to antidepressant effect) Neuroleptic malignant syndrome (when overlapping with malignant catatonia) Severe aggression in intellectual disability or autism (when pharmacotherapy fails) Patient preference (some patients request ECT based on prior good response)

Technique

Pre-ECT Evaluation

Medical workup: CBC, CMP, ECG, chest X-ray (if indicated), spine imaging if structural concerns. Anesthesia evaluation: airway assessment, medication review (especially lithium -- hold on morning of ECT due to toxicity risk with post-ictal fluid shifts; theophylline increases seizure duration) Informed consent: detailed discussion of risks (cognitive effects especially), benefits, alternatives, expected number of treatments. Medications to adjust:. Benzodiazepines and anticonvulsants raise seizure threshold -- taper or hold if clinically safe. Lithium: hold on day of treatment (risk of prolonged confusion, neurotoxicity) Theophylline: hold (risk of prolonged seizures) MAOIs: can generally continue with anesthesia precautions.

Electrode Placement

Right unilateral (RUL): both electrodes on the non-dominant (right) hemisphere; preferred initial placement due to fewer cognitive side effects. Must be dosed at 6x seizure threshold to achieve efficacy comparable to bilateral placement (Sackeim et al. 2000) Ultra-brief pulse (0.3 ms) RUL has the best cognitive profile. Bifrontotemporal (bilateral, BT): one electrode on each temple; most robust antidepressant efficacy; greater cognitive side effects. May be used as first-line for severe/psychotic depression or when rapid response is critical. Bifrontal (BF): electrodes on both frontal regions; may have intermediate cognitive profile; evidence for comparable efficacy to BT is mixed.

Stimulus Parameters

Brief pulse (0.5-1.0 ms): standard pulse width; adequate seizure quality with moderate cognitive effects. Ultra-brief pulse (0.3 ms): used with RUL placement; significantly reduces cognitive side effects while maintaining efficacy at suprathreshold dosing. Seizure threshold titration: performed at first treatment to determine minimum charge needed to induce a seizure; subsequent treatments dosed as a multiple of this threshold. Adequate seizure duration: generalized motor seizure lasting >=15-20 seconds (EEG seizure >=25 seconds); post-ictal suppression on EEG is a marker of seizure quality.

Anesthesia and Procedure

Induction agent: methohexital (preferred -- shortest acting, least seizure threshold elevation), propofol (raises threshold more), etomidate (lowers threshold -- useful for high-threshold patients), ketamine (growing interest for synergistic antidepressant effect) Muscle relaxant: succinylcholine (depolarizing agent; brief duration; observe for hyperkalemia risk) Anticholinergic: glycopyrrolate to manage secretions and vagal bradycardia. Ventilation: pre-oxygenation with 100% O2; assisted ventilation throughout; hyperventilation lowers seizure threshold (useful) Monitoring: pulse oximetry, ECG, EEG, EMG (cuff technique on one limb to monitor motor seizure)

Treatment Course

Acute series: typically 6-12 treatments, administered 2-3 times per week. Most patients begin to respond after 3-4 treatments; full response by 6-8. If no response after 6-8 treatments, reassess (electrode placement change, stimulus parameters, or consider treatment failure) Maintenance ECT: weekly to monthly treatments to prevent relapse in patients who responded to acute ECT and are at high relapse risk.

Cognitive Side Effects

Acute Cognitive Effects

Post-ictal confusion: disorientation lasting minutes to hours after each treatment; resolves fully between sessions. Anterograde amnesia: difficulty forming new memories during the treatment course; typically resolves within 2-4 weeks of completing ECT. Retrograde amnesia: loss of memories from the period surrounding the treatment course (weeks to months); largely resolves but some persistent gaps may remain, particularly for autobiographical memory.

Risk Factors for Greater Cognitive Impact

Bilateral (BT) > right unilateral (RUL) > bifrontal (BF) electrode placement. Brief pulse > ultra-brief pulse width. Higher stimulus charge, more frequent treatments (3x/week > 2x/week) Pre-existing cognitive impairment (e.g., elderly with neurodegenerative disease)

Minimizing Cognitive Effects

Ultra-brief pulse RUL as default first-line approach. Space treatments to 2x/week when clinically feasible. Use the lowest effective suprathreshold charge. Monitor cognition formally (Mini-Mental Status Exam or MoCA at baseline and periodically) Switch from bilateral to RUL if cognitive effects are intolerable and depression has partially responded.

Informed Consent Considerations

Patients must understand: the procedure, anesthesia risks, cognitive side effects (especially amnesia), alternatives, expected number of treatments, right to withdraw consent at any time. Capacity to consent should be assessed -- patients with severe depression or psychosis may lack capacity; surrogate consent may be needed. Document the consent process thoroughly, including specific discussion of memory effects. Involuntary ECT is legally permissible in some jurisdictions for life-threatening psychiatric illness (e.g., malignant catatonia, refusal to eat) but requires court authorization in most states.

<image> A diagram showing the three main electrode placements for ECT: right unilateral (d'Elia placement), bifrontotemporal (bilateral), and bifrontal. Use a top-down view of the head for each placement with electrode positions clearly marked. Below each placement, include a comparison panel showing relative efficacy (bar graph), cognitive side effect burden (bar graph), and recommended stimulus parameters (pulse width, dosing relative to seizure threshold). Color-coded for clarity. </image>

<image> A step-by-step procedure infographic for an ECT treatment session. Show the sequence: pre-procedure checklist (NPO status, medication review, consent), anesthesia induction (IV methohexital + succinylcholine + glycopyrrolate), pre-oxygenation and hyperventilation, stimulus delivery, seizure monitoring (EEG, EMG cuff technique), post-ictal recovery and assessment. Include timing annotations and monitoring parameters at each step. Clean medical procedure format. </image>

<image> A graph comparing the efficacy and cognitive side effect profiles of different ECT modalities. X-axis: cognitive side effects (low to high). Y-axis: antidepressant efficacy (low to high). Plot: ultra-brief pulse RUL at 6x threshold (low cognitive, good efficacy), brief pulse RUL (moderate cognitive, good efficacy), bilateral BT (high cognitive, highest efficacy), bifrontal (intermediate on both axes). Include data point labels with response rates from key trials (Sackeim et al. 2000, 2008). Scatter plot format with quadrant labels. </image>

Clinical Pearls

ECT is the single most effective treatment for severe depression, especially with psychotic features -- response rates of 80-90% are unmatched by any pharmacotherapy. Stigma remains the biggest barrier to ECT use -- educate patients that modern ECT under general anesthesia bears little resemblance to historical or media portrayals. Ultra-brief pulse right unilateral ECT at 6x seizure threshold is the default starting approach: it preserves cognitive function while maintaining strong efficacy. Hold lithium on the morning of ECT -- post-ictal lithium toxicity and prolonged confusion are well-documented risks. ECT during pregnancy is considered one of the safest treatment options for severe psychiatric illness -- it avoids fetal drug exposure while treating the mother. Maintenance ECT (weekly to monthly) is an underutilized strategy for relapse prevention in patients with recurrent treatment-resistant depression. Always obtain a baseline cognitive assessment before starting ECT -- this protects both the patient and the clinician by establishing pre-treatment function.

References

• Sackeim HA, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425-434.
• Kellner CH, et al. ECT in treatment-resistant depression. Am J Psychiatry. 2012;169(12):1238-1244.
• APA Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. 2nd ed. APA; 2001.
• Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007;357(19):1939-1945.
• Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568-577.

Read this lecture as Markdown